Harrow Health Inc's stock plummeted 13.26% in pre-market trading on Tuesday.
The sharp decline was driven by the company's release of first-quarter 2026 financial results, which significantly missed analyst expectations. Harrow reported a loss of $0.74 per share, much worse than the consensus estimate of a $0.39 loss, while revenue of $44.2 million fell 15.68% short of the $52.4 million forecast. The company's net loss widened to $27.6 million, and gross margin contracted to 61% from 68% a year earlier.
Management attributed part of the revenue shortfall to a non-recurring $8 million gross-to-net adjustment related to new commercial coverage for its VEVYE product. Despite the disappointing quarterly performance, the company reaffirmed its full-year 2026 revenue guidance and projected improved second-quarter revenue.
Comments